Mahindra Manulife Small Cap Fund
The Scheme seeks to generate long term capital appreciation by investing in a diversified portfolio of equity & equity related securities of small cap companies.
Growthvine rating: 4/5 — ranked #5 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹21.82 (as of 2026-10-01) |
|---|
| AUM | ₹5,087 Cr |
|---|
| Expense ratio | 1.59% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Krishna Sanghavi |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| Sharpe ratio | 0.74 |
|---|
| Standard deviation | 19.67% |
|---|
| Max drawdown | −26.44% |
|---|
| Alpha | 4.85 |
|---|
| Beta | 0.88 |
|---|
Over 5 years, captured 97.8% of NIFTY Smallcap 250's upside and 76.5% of its downside.
Market cap allocation
| Large cap | 10.7% |
|---|
| Mid cap | 23.1% |
|---|
| Small cap | 66.2% |
|---|
Concentration
| Top 5 holdings | 20.2% |
|---|
| Top 10 holdings | 31.7% |
|---|
| Total holdings | 81 |
|---|
| Index overlap | 16.5% |
|---|
| Active share | 83.5% |
|---|
Top holdings
- Multi Commodity Exchange of India Ltd — 5.8%
- Neuland Laboratories Limited. — 4.3%
- Divis Laboratories Ltd. — 3.7%
- Triparty Repo — 3.5%
- Jindal Saw Ltd. — 3.5%
- GARWARE HI-TECH FILMS LIMITED — 2.9%
- Oil India Limited — 2.6%
- VOLTAMP TRANSFORMERS LIMITED — 2.5%
- Arvind Ltd. — 2.4%
- Usha Martin Ltd. — 2.0%
Top sectors
- Pharma & Biotech — 15.6%
- Industrial Products — 14.6%
- Banking & Financial — 11.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.4% | Q2 | #16 of 34 |
| 2025 | −2.7% | Q2 | #11 of 30 |
| 2024 | 28.0% | Q2 | #9 of 28 |
| 2023 | 57.2% | Q1 (Top) | #1 of 24 |